Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL, Trněný M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, Delwail V, Rodriguez G, Venugopal P, Coleman M, Dartigeas C, Patti C, Pane F, Jurczak W, Taszner M, Paneesha S, Zheng F, DeMarini DJ, Jiang W, Gilmartin A, Mehta A. Zinzani PL, et al. Among authors: coleman m. EClinicalMedicine. 2023 Aug 10;62:102131. doi: 10.1016/j.eclinm.2023.102131. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37599908 Free PMC article.
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM. Hamadani M, et al. Among authors: coleman m. Hematol Oncol. 2023 Dec;41(5):848-857. doi: 10.1002/hon.3209. Epub 2023 Jul 26. Hematol Oncol. 2023. PMID: 37496298 Clinical Trial.
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Among authors: coleman m. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
Cell-Free Screening, Production and Animal Testing of a STI-Related Chlamydial Major Outer Membrane Protein Supported in Nanolipoproteins.
Mohagheghi M, Abisoye-Ogunniyan A, Evans AC, Peterson AE, Bude GA, Hoang-Phou S, Vannest BD, Hall D, Rasley A, Weilhammer DR, Fischer NO, He W, Robinson BV, Pal S, Slepenkin A, de la Maza L, Coleman MA. Mohagheghi M, et al. Among authors: coleman ma. Vaccines (Basel). 2024 Nov 1;12(11):1246. doi: 10.3390/vaccines12111246. Vaccines (Basel). 2024. PMID: 39591149 Free PMC article.
Long-lasting residual efficacy of a new indoor residual spraying product, VECTRON™ T500 (broflanilide), against pyrethroid-resistant malaria vectors and its acceptance in a community trial in Burkina Faso.
Hien AS, Bayili K, Maiga S, Oumbouke W, Birba J, Soma DD, Ouattara AY, Karama DO, Coleman M, Snetselaar J, Small G, Niimi S, Ayumi K, Kompaoré S, Tsuchiya K, Dabiré RK, Diabaté A. Hien AS, et al. Among authors: coleman m. Parasit Vectors. 2024 Nov 23;17(1):484. doi: 10.1186/s13071-024-06577-y. Parasit Vectors. 2024. PMID: 39580476 Free PMC article. Clinical Trial.
2,948 results